Cargando…
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome...
Autores principales: | Leach, M O, Brindle, K M, Evelhoch, J L, Griffiths, J R, Horsman, M R, Jackson, A, Jayson, G C, Judson, I R, Knopp, M V, Maxwell, R J, McIntyre, D, Padhani, A R, Price, P, Rathbone, R, Rustin, G J, Tofts, P S, Tozer, G M, Vennart, W, Waterton, J C, Williams, S R, Workman, P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362033/ https://www.ncbi.nlm.nih.gov/pubmed/15870830 http://dx.doi.org/10.1038/sj.bjc.6602550 |
Ejemplares similares
-
Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006) -
Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging
por: Robinson, S P, et al.
Publicado: (2003) -
Antiangiogenic drugs in ovarian cancer
por: Kumaran, G C, et al.
Publicado: (2009) -
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments
por: Nielsen, Thomas, et al.
Publicado: (2012) -
Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
por: Sassa, Yukio, et al.
Publicado: (2010)